{
    "2019-04-28": [
        [
            {
                "time": "",
                "original_text": "【东吴医药】华兰生物2019年一季报点评：血液制品行业回暖，拉动一季度业绩增速25%超预期",
                "features": {
                    "keywords": [
                        "华兰生物",
                        "血液制品",
                        "行业回暖",
                        "业绩增速",
                        "超预期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "反弹一触即发？利空被澄清，五一节前“业绩雷”将爆完，4月聪明钱“爆买”这些股！",
                "features": {
                    "keywords": [
                        "反弹",
                        "利空澄清",
                        "业绩雷",
                        "聪明钱",
                        "爆买"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：继续推荐3+2主线 荐2股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "3+2主线",
                        "荐股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗保健"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：震荡做底后将挑战前高 荐6股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "震荡做底",
                        "挑战前高",
                        "荐股"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗保健"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：关注创新题材及业绩高速增长个股机会 荐14股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "创新题材",
                        "业绩增长",
                        "个股机会",
                        "荐股"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗保健"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "跑输各自业绩比较基准 兴银国都九泰三产品问题曝光",
                "features": {
                    "keywords": [
                        "跑输",
                        "业绩比较基准",
                        "产品问题",
                        "曝光"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【国盛医药张金洋团队】详解2019Q1机构医药持仓，继续推荐医药流通",
                "features": {
                    "keywords": [
                        "国盛医药",
                        "机构持仓",
                        "医药流通",
                        "推荐"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【国信医药|年报暨一季报点评】博雅生物：符合预期，期待调浆获批",
                "features": {
                    "keywords": [
                        "博雅生物",
                        "年报",
                        "一季报",
                        "调浆获批",
                        "符合预期"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "华兰生物:血制品供需格局趋于稳定,助公司稳健增长",
                "features": {
                    "keywords": [
                        "华兰生物",
                        "血制品",
                        "供需格局",
                        "稳定",
                        "稳健增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "华兰生物:业绩增长略超预期,血制品增长有望超预期",
                "features": {
                    "keywords": [
                        "华兰生物",
                        "业绩增长",
                        "略超预期",
                        "血制品",
                        "有望超预期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}